Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study

2013 ◽  
Vol 108 (2) ◽  
pp. S81-S82
Author(s):  
Raphael Schiffmann ◽  
Gregory Pastores ◽  
Chang Peter ◽  
Martin Rick ◽  
Wijatyk Anna
Keyword(s):  
Fabry Disease ◽  
Pediatric Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Agalsidase Alfa

Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study

2021 ◽  
Vol 132 (2) ◽  
pp. S65
Author(s):  
Ales Linhart ◽  
Gabriela Dostalova ◽  
Kathy Nicholls ◽  
Michael West ◽  
Camilla Tøndel ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Agalsidase Alfa ◽  
Treatment Data

Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study

2020 ◽  
Vol 129 (2) ◽  
pp. S98-S99
Author(s):  
Ales Linhart ◽  
Gabriela Dostalova ◽  
Kathy Nicholls ◽  
Michael West ◽  
Camilla Tøndel ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Phase Iii ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Agalsidase Alfa ◽  
Treatment Data ◽  
One Year

Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study

2011 ◽  
Vol 21 (3) ◽  
pp. 229-236 ◽  
Author(s):  
Ronald N. Marcus ◽  
Randall Owen ◽  
George Manos ◽  
Raymond Mankoski ◽  
Lisa Kamen ◽  
...  
Keyword(s):  
Autistic Disorder ◽  
Pediatric Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document